Evidence map›Paper›PMID 19261608›Full record

ArticleThe Journal of biological chemistry2009

Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.

Isao Hirano, Satoki Nakamura, Daisuke Yokota, Takaaki Ono, Kazuyuki Shigeno, Shinya Fujisawa, Kaori Shinjo, Kazunori Ohnishi

RetractedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Modulated Gene Expression ofThe Korean journal of parasitology · 2018
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Guide to virtual screening: application to the Akt phosphatase PHLPP.Methods in molecular biology (Clifton, N.J.) · 2012
    Article
  9. PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1.Biochemical and biophysical research communications · 2011
    Article
  10. Article
  11. Protein kinase signaling networks in cancer.Current opinion in genetics & development · 2011
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Isao HiranoDepartment of Internal Medicine III, Hamamatsu, Shizuoka 431-3192, Japan; Cancer Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan.
Satoki NakamuraDepartment of Internal Medicine III, Hamamatsu, Shizuoka 431-3192, Japan.
Daisuke YokotaDepartment of Internal Medicine III, Hamamatsu, Shizuoka 431-3192, Japan; Cancer Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan.
Takaaki OnoDepartment of Internal Medicine III, Hamamatsu, Shizuoka 431-3192, Japan; Cancer Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan.
Kazuyuki ShigenoDepartment of Internal Medicine III, Hamamatsu, Shizuoka 431-3192, Japan.
Shinya FujisawaDivision of Hematology, Hamamatsu Medical Center, 328 Tomitsuka, Naka-ku, Hamamatsu, Shizuoka 432-8580, Japan.
Kaori ShinjoDepartment of Internal Medicine III, Hamamatsu, Shizuoka 431-3192, Japan.
Kazunori OhnishiDepartment of Internal Medicine III, Hamamatsu, Shizuoka 431-3192, Japan; Cancer Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan.
Hamamatsu University School of Medicine · JPHamamatsu Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway commonly occurs in cancers and is a crucial event in tumorigenesis. Chronic myelogenous leukemia (CML) is characterized by a reciprocal chromosomal translocation (9;22) that generates the Bcr-Abl fusion gene. The PI3K/Akt pathway is activated by Bcr-Abl chimera protein and mediates the leukemogenesis in CML. However, the mechanism by which Bcr-Abl activates the PI3K/Akt pathway is not completely understood. In the present study, we found that pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 (PHLPP1 and PHLPP2) were depleted in CML cells. We investigated the interaction between PHLPPs and Bcr-Abl in CML cell lines and Bcr-Abl+ progenitor cells from CML patients. The Abl kinase inhibitors and depletion of Bcr-Abl induced the expression of PHLPP1 and PHLPP2, which dephosphorylated Ser-473 on Akt1, -2, and -3, resulting in inhibited proliferation of CML cells. The reduction of PHLPP1 and PHLPP2 expression by short interfering RNA in CML cells weakened the Abl kinase inhibitor-mediated inhibition of proliferation. In colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte; colony-forming unit-granulocyte, macrophage; and burst-forming unit-erythroid, treatment with the Abl kinase inhibitors and depletion of Bcr-Abl induced PHLPP1 and PHLPP2 expression and inhibited colony formation of Bcr-Abl+ progenitor cells, whereas depletion of PHLPP1 and PHLPP2 weakened the inhibition of colony formation activity by the Abl kinase inhibitors in Bcr-Abl+ progenitor cells. Thus, Bcr-Abl represses the expression of PHLPP1 and PHLPP2 and continuously activates Akt1, -2, and -3 via phosphorylation on Ser-473, resulting in the proliferation of CML cells.

Indexed as

Gene Expression Regulation, NeoplasticCell Line, TumorCell ProliferationFusion Proteins, bcr-ablHL-60 CellsHumansK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNuclear ProteinsPhosphatidylinositol 3-KinasesPhosphoprotein PhosphatasesPhosphorylationProtein IsoformsProto-Oncogene Proteins c-aktU937 CellsFusion Proteins, bcr-ablNuclear ProteinsPHLPP1 protein, humanPHLPP2 protein, humanPhosphatidylinositol 3-KinasesPhosphoprotein PhosphatasesProtein IsoformsProto-Oncogene Proteins c-akt

Identifiers

PMID19261608
PMCPMC2755940
OpenAlexW1977295404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.